Free Radic Biol Med 2014
Researchers analyzed data from 753 people with obesity who initiated a GLP-1 medication
Looking to the Future As the GLP-1 market matures, ESG risks could decline
For example, the SELECT trial showed a 20% improvement in major cardiovascular events (i.e., heart attacks, strokes, and deaths from those cases) in adults on weekly semaglutide who were overweight or obese (without diabetes) and with preexisting cardiovascular disease, as well as an improvement in all-cause mortality of 19%
However, note that if your case is based on negligence, you will likely only have two years to file a personal injury lawsuit
What to Expect While on GLP-1 Therapy Like any medication, GLP-1 injections can cause temporary side effects, most often including mild nausea, fatigue, or digestive changes